FDA Rejects TransEnterix’ 510(k) For Surgibot
This article was originally published in Clinica
The US FDA has notified TransEnterix that the SurgiBot single-port, robotically enhanced laparoscopic surgical platform does not meet the criteria for substantial equivalence, according to the company.
You may also be interested in...
SENZA PDN showed Nevro's HF10 spinal cord stimulation therapy provided sustained relief to patients with painful diabetic neuropathy. Results of a separate trial showed HF10 improved outcomes in patients with non-surgical refractory back pain.
Boston Scientific’s WaveWriter Alpha spinal cord stimulation devices feature the proprietary FAST software for rapid, paresthesia-free pain relief of chronic pain.
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the final day of the meeting.